ANGLE PLC

Delisting Announcement • Oct 31, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7752V

Angle PLC

31 October 2014

For immediate release	31 October 2014

ANGLE plc

("ANGLE" or the "Company")

ADR PROGRAMME

ANGLE plc (AIM: AGL; OTCQX: ANPCY), the specialist medtech company, is pleased to announce that effective 9.30am EST today, 31 October 2014, the Company's American Depositary Receipts (ADRs) will begin trading under the symbol ANPCY on the OTCQX marketplace in the United States.

The ADRs will trade in US dollars with each ADR representing 10 ANGLE plc ordinary shares.  ANGLE's ordinary shares will continue to trade in British pounds on the London Stock Exchange's AIM market.

Trading on OTCQX is intended to enhance ANGLE's US market exposure and trading visibility and to increase liquidity.  It allows investors to hold their shares and settle their trades through the US settlement systems, in common with any other US stock.

Aegis Capital Corp. is ANGLE's Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements. The Bank of New York Mellon is acting as the depositary to establish and maintain the ADR programme. 

A list of frequently asked questions in relation to the ADR programme will be provided on the Company's website in the investor section.

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We believe that the steps that we are taking will substantially strengthen ANGLE's position in the United States, the world's largest market for medical diagnostics.  The ADR programme on the OTCQX marketplace will meet US investor demand and increase liquidity in ANGLE's shares to the benefit of our shareholders."

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Stephen Keys, Dr Christopher Golden (Nominated adviser) Andy Roberts, Christian Hobart (Sales)	020 7397 8900
Buchanan Mark Court, Sophie Cowles	020 7466 5000

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCQKKDKDBDBAKN